The BCORL1 Knockout SK-HEP-1 Polyclonal Cells product represents a CRISPR/Cas9-mediated polyclonal knockout cell population derived from the human SK-HEP-1 endothelial-like cell line, engineered to disrupt the BCORL1 gene. This loss-of-function model enables systematic investigation of BCORL1-dependent transcriptional regulation and its impact on endothelial cell biology. The polyclonal composition reflects a mixed population of cells harboring diverse genomic edits at the target locus, providing a robust system for studying gene function without clonal bias. Researchers can employ this model to dissect the molecular mechanisms governing BCORL1 activity in cancer-related and developmental contexts, utilizing standard cell culture conditions and established endothelial assays.
The host cell line SK-HEP-1 originates from the ascitic fluid of a patient with liver adenocarcinoma and exhibits an endothelial-like phenotype characterized by expression of endothelial markers, angiogenic potential, and responsiveness to vascular stimuli. This cell line has been widely adopted as a surrogate for primary endothelial cells in studies of angiogenesis, migration, vascular permeability, and tumor?Cendothelial interactions. Its stable growth properties and amenability to genetic manipulation make it a versatile platform for loss-of-function screens, signaling pathway analysis, and phenotypic characterization of endothelial dysfunction. The SK-HEP-1 background thus provides a clinically relevant context for assessing the consequences of BCORL1 ablation in a liver cancer-derived endothelial model.
BCORL1 encodes a transcriptional corepressor that associates with the BCL6 transcriptional repressor and class II histone deacetylases (HDAC4, HDAC5, HDAC7, HDAC9) to form a multisubunit repression complex also containing NCOR1, NCOR2, and SMRT. This complex modulates gene expression programs controlling cell cycle progression, apoptosis, and differentiation by deacetylating histones at target promoters. BCORL1 activity is regulated upstream by the Notch signaling pathway and BCL6, and it directly represses key downstream effectors such as CDKN1A (p21), BCL2, and Notch target genes. Through these interactions, BCORL1 participates in maintaining hematopoietic stem cell homeostasis and embryonic development, and its dysregulation is implicated in myelodysplastic syndromes, acute myeloid leukemia, and other hematologic malignancies. In endothelial cells, BCORL1 may influence transcriptional networks governing angiogenic sprouting, quiescence, and inflammatory responses.
Knockout of BCORL1 in SK-HEP-1 cells likely disrupts normal corepressor complex function, derepressing target genes and altering the endothelial transcriptome. This can manifest in phenotypic changes such as enhanced or suppressed proliferation, modified migratory behavior, altered tube formation capacity, and shifted cell cycle profiles. The endothelial-like nature of SK-HEP-1 permits the model to bridge the gap between hematologic malignancy research and vascular biology, offering insights into how BCORL1 loss contributes to tumor microenvironment remodeling and aberrant angiogenesis. Additionally, this system serves as a tool to explore crosstalk between Notch, Hippo, and BCORL1-mediated transcriptional repression pathways in an endothelial context, providing a platform for identifying new therapeutic targets.
Typical applications include transcriptome-wide analyses via RNA-seq to map BCORL1-dependent gene networks, chromatin immunoprecipitation (ChIP-qPCR) to assess corepressor occupancy at specific loci, and co-immunoprecipitation to verify interactions with BCL6 and HDAC partners. Functional studies may involve endothelial tube formation assays, migration and invasion assays, and flow cytometry-based cell cycle profiling. The model is suited for drug screening efforts aimed at hematologic malignancies or angiogenesis inhibitors, where BCORL1 status may predict sensitivity to HDAC inhibitors or Notch pathway modulators. For additional details or technical support, please contact Ascent Research.
